CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY $ in Thousands		USD ($) shares	Common Stock USD ($) shares		Additional Paid-In Capital USD ($)	Accumulated Deficit USD ($)	Accumulated Other Comprehensive Loss USD ($)	Total UpHealth, Inc. Stockholders’ Equity USD ($)	Noncontrolling Interests USD ($)
Beginning balance (in shares) at Dec. 31, 2019 | shares	[1]		0
Beginning balance at Dec. 31, 2019	[1]	$ 0	$ 0		$ 0	$ 0	$ 0	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for formation (in shares) | shares	[1]		50,050,000
Issuance of common stock for formation	[1]	0	$ 5		(5)
Net income (loss)		(203)				(203)		(203)
Ending balance (in shares) at Mar. 31, 2020 | shares	[1]		50,050,000
Ending balance at Mar. 31, 2020	[1]	(203)	$ 5		(5)	(203)	0	(203)	0
Beginning balance (in shares) at Dec. 31, 2019 | shares	[1]		0
Beginning balance at Dec. 31, 2019	[1]	0	$ 0		0	0	0	0	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(1,060)
Foreign currency translation adjustments		0
Ending balance (in shares) at Sep. 30, 2020 | shares			50,050,000
Ending balance at Sep. 30, 2020		(1,060)	$ 5		(5)	(1,060)	0	(1,060)	0
Beginning balance (in shares) at Mar. 31, 2020 | shares	[1]		50,050,000
Beginning balance at Mar. 31, 2020	[1]	(203)	$ 5		(5)	(203)	0	(203)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(336)				(336)		(336)
Ending balance (in shares) at Jun. 30, 2020 | shares	[1]		50,050,000
Ending balance at Jun. 30, 2020	[1]	(539)	$ 5		(5)	(539)	0	(539)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(521)				(521)		(521)
Foreign currency translation adjustments		0
Ending balance (in shares) at Sep. 30, 2020 | shares			50,050,000
Ending balance at Sep. 30, 2020		$ (1,060)	$ 5		(5)	(1,060)	0	(1,060)	0
Beginning balance (in shares) at Dec. 31, 2020 | shares		70,021,000	70,021,000	[1]
Beginning balance at Dec. 31, 2020	[1]	$ 220,721	$ 7		222,900	(2,186)	0	220,721	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock to consummate business combinations (in shares) | shares	[1]		8,749,000
Issuance of common stock to consummate business combinations	[1]	104,798	$ 1		87,408			87,409	17,389
Net income (loss)		(3,028)				(2,950)		(2,950)	(78)
Foreign currency translation adjustments		(1,159)					(1,159)	(1,159)
Ending balance (in shares) at Mar. 31, 2021 | shares	[1]		78,771,000
Ending balance at Mar. 31, 2021	[1]	$ 321,332	$ 8		310,308	(5,136)	(1,159)	304,021	17,311
Beginning balance (in shares) at Dec. 31, 2020 | shares		70,021,000	70,021,000	[1]
Beginning balance at Dec. 31, 2020	[1]	$ 220,721	$ 7		222,900	(2,186)	0	220,721	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(2,994)
Foreign currency translation adjustments		$ (3,459)
Ending balance (in shares) at Sep. 30, 2021 | shares		117,800,353	117,800,000
Ending balance at Sep. 30, 2021		$ 628,920	$ 12		621,861	(5,328)	(3,459)	613,086	15,834
Beginning balance (in shares) at Mar. 31, 2021 | shares	[1]		78,771,000
Beginning balance at Mar. 31, 2021	[1]	321,332	$ 8		310,308	(5,136)	(1,159)	304,021	17,311
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock to consummate business combinations (in shares) | shares			26,162,000
Issuance of common stock to consummate business combinations		241,885	$ 3		243,584			243,587	(1,702)
Merger recapitalization (in shares) | shares			9,471,000
Merger recapitalization		54,605	$ 1		54,604			54,605
PIPE common stock issuance (in shares) | shares			3,000,000
PIPE common stock issuance		27,079			27,079			27,079
Forward share repurchase agreement		(17,000)			(17,000)			(17,000)
Issuance of common stock for debt conversion (in shares) | shares			200,000
Issuance of common stock for debt conversion		1,879			1,879			1,879
Net income (loss)		(32,790)				(32,784)		(32,784)	(6)
Foreign currency translation adjustments		(2,319)					(2,319)	(2,319)
Ending balance (in shares) at Jun. 30, 2021 | shares			117,605,000
Ending balance at Jun. 30, 2021		$ 594,672	$ 12		620,455	(37,920)	(3,478)	579,069	15,603
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exchange ratio		10.28
Ending balance (in shares) at Sep. 30, 2021 | shares		117,800,353	117,800,000
Ending balance at Sep. 30, 2021		$ 628,920	$ 12		621,861	(5,328)	(3,459)	613,086	15,834
Beginning balance (in shares) at Jun. 30, 2021 | shares			117,605,000
Beginning balance at Jun. 30, 2021		594,672	$ 12		620,455	(37,920)	(3,478)	579,069	15,603
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Purchase consideration adjustment		677			677			677
Exercise of stock options, net (in shares) | shares			196,000
Exercise of stock option, net		319			319			319
Stock-based compensation		410			410			410
Net income (loss)		32,823				32,592		32,592	231
Foreign currency translation adjustments		$ 19					19	19
Ending balance (in shares) at Sep. 30, 2021 | shares		117,800,353	117,800,000
Ending balance at Sep. 30, 2021		$ 628,920	$ 12		$ 621,861	$ (5,328)	$ (3,459)	$ 613,086	$ 15,834

[1] (1) Amounts as of March 31, 2021 and before that date differ from those published in prior consolidated financial statements as they were retrospectively adjusted as a result of the accounting for the Business Combinations (as defined below in Note 1). Specifically, the number of common shares outstanding during periods before the Business Combinations are computed on the basis of the number of common shares of UpHealth Holdings (accounting acquiror) during those periods multiplied by the exchange ratio established in the stock purchase agreement (1.00 UpHealth Holdings shares converted to 10.28 GigCapital2 shares). Common stock and additional paid-in capital were adjusted accordingly.